Comparison · NCT00429364-sae
Atenolol vs Losartan: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Atenolol vs Losartan: serious adverse events. Trial comparisons, record NCT00429364-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00429364-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0891 | 0.062 | 0.127 | wilson | |
| Risk in group 2 | 0.108 | 0.0781 | 0.148 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0191 | -0.0673 | 0.029 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.824 | 0.508 | 1.34 | log | |
| Odds ratio, group 1 over group 2 | 0.806 | 0.472 | 1.38 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Atenolol than on Losartan | 52.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Atenolol | Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate. | 27 | 303 | EG000 |
| Group 2 | Losartan | Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg). | 33 | 305 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- The adverse event (AE) data were collected since randomization till the end of the study, for up to 3 years.
Source ClinicalTrials.gov
Trial
- Title
- Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome
- NCT number
- NCT00429364
- Phases
- PHASE3
- Conditions
- Marfan Syndrome
- Interventions
- Losartan Potassium, Atenolol
- Lead sponsor
- Carelon Research
- Results first posted
- 2015-04-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00429364?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00429364-sae